STOCK TITAN

[Form 4] Identive, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Select Medical Holdings Corp. (SEM) Form 4: Chief Information Officer Brian R. Rusignuolo reported the grant of 75,000 shares of common stock on 29-Jul-2025. The award is restricted stock that will vest in full on 29-Jul-2028, subject to customary exceptions. No cash was paid (reported price $0), indicating an equity-based compensation grant rather than an open-market purchase.

Following the transaction, Rusignuolo’s direct beneficial ownership stands at 376,050 SEM shares. No derivative securities were involved and there were no dispositions.

  • Form filed by one reporting person; no Rule 10b5-1 indication.
  • Transaction code “A” denotes an award rather than market activity.
  • The grant aligns executive interests with shareholders but represents a small fraction of SEM’s outstanding shares (exact float not disclosed in the filing).

Select Medical Holdings Corp. (SEM) Modulo 4: Il Chief Information Officer Brian R. Rusignuolo ha segnalato la concessione di 75.000 azioni ordinarie il 29-lug-2025. L'assegnazione consiste in azioni vincolate che matureranno completamente il 29-lug-2028, salvo consuete eccezioni. Non è stato pagato alcun importo in contanti (prezzo segnalato $0), indicando una remunerazione basata su azioni piuttosto che un acquisto sul mercato aperto.

Dopo questa operazione, la proprietà diretta di Rusignuolo ammonta a 376.050 azioni SEM. Non sono stati coinvolti strumenti derivati né ci sono state cessioni.

  • Modulo presentato da una sola persona che segnala; nessuna indicazione di Regola 10b5-1.
  • Il codice transazione “A” indica un premio e non un'attività di mercato.
  • La concessione allinea gli interessi del dirigente con quelli degli azionisti, ma rappresenta una piccola frazione delle azioni in circolazione di SEM (la quantità esatta non è stata divulgata nel modulo).

Select Medical Holdings Corp. (SEM) Formulario 4: El Director de Información Brian R. Rusignuolo reportó la concesión de 75,000 acciones ordinarias el 29-jul-2025. La adjudicación corresponde a acciones restringidas que se consolidarán completamente el 29-jul-2028, sujeto a excepciones habituales. No se pagó efectivo (precio reportado $0), lo que indica una compensación basada en acciones en lugar de una compra en el mercado abierto.

Tras la transacción, la propiedad directa beneficiaria de Rusignuolo es de 376,050 acciones SEM. No se involucraron valores derivados ni hubo disposiciones.

  • Formulario presentado por una sola persona informante; sin indicación de la Regla 10b5-1.
  • El código de transacción “A” denota una adjudicación y no actividad de mercado.
  • La concesión alinea los intereses ejecutivos con los de los accionistas, pero representa una pequeña fracción de las acciones en circulación de SEM (el flotante exacto no se divulgó en el formulario).

Select Medical Holdings Corp. (SEM) Form 4: 최고정보책임자 브라이언 R. 루시뉴올로는 2025년 7월 29일에 75,000주의 보통주 부여를 신고했습니다. 이 수상은 제한 주식으로 2028년 7월 29일에 완전히 권리가 확정되며, 일반적인 예외 조건이 적용됩니다. 현금 지급은 없었으며(보고된 가격 $0), 이는 공개 시장에서의 매입이 아닌 주식 기반 보상임을 나타냅니다.

거래 후 루시뉴올로의 직접적 실소유 주식은 376,050 SEM 주식입니다. 파생 증권은 포함되지 않았으며 처분도 없었습니다.

  • 신고자 한 명이 제출한 서식; Rule 10b5-1 관련 표시는 없음.
  • 거래 코드 “A”는 시장 활동이 아닌 상여를 의미합니다.
  • 이번 부여는 경영진과 주주간 이해관계를 일치시키지만 SEM의 유통 주식 중 극히 일부에 해당합니다(정확한 유통 주식 수는 제출서류에 공개되지 않음).

Select Medical Holdings Corp. (SEM) Formulaire 4 : Le Directeur des Systèmes d'Information, Brian R. Rusignuolo, a déclaré l'octroi de 75 000 actions ordinaires le 29 juillet 2025. Cette attribution concerne des actions restreintes qui seront entièrement acquises le 29 juillet 2028, sous réserve des exceptions habituelles. Aucun paiement en espèces n'a été effectué (prix déclaré 0 $), ce qui indique une rémunération en actions plutôt qu'un achat sur le marché libre.

Après cette opération, la détention directe de Rusignuolo s'élève à 376 050 actions SEM. Aucun instrument dérivé n'a été impliqué et aucune cession n'a eu lieu.

  • Formulaire déposé par une seule personne déclarant ; aucune indication de la règle 10b5-1.
  • Le code de transaction « A » désigne une attribution et non une activité de marché.
  • L'attribution aligne les intérêts de la direction avec ceux des actionnaires, mais représente une faible fraction des actions en circulation de SEM (le flottant exact n'est pas divulgué dans le formulaire).

Select Medical Holdings Corp. (SEM) Formular 4: Chief Information Officer Brian R. Rusignuolo meldete die Gewährung von 75.000 Stammaktien am 29. Juli 2025. Die Zuteilung besteht aus eingeschränkten Aktien, die am 29. Juli 2028 vollständig unverfallbar sind, vorbehaltlich üblicher Ausnahmen. Es wurde kein Bargeld gezahlt (gemeldeter Preis $0), was auf eine aktienbasierte Vergütung und keinen Kauf am offenen Markt hinweist.

Nach der Transaktion hält Rusignuolo direkt 376.050 SEM-Aktien. Es waren keine Derivate beteiligt und es gab keine Veräußerungen.

  • Formular wurde von einer meldenden Person eingereicht; keine Angabe zu Regel 10b5-1.
  • Transaktionscode „A“ steht für eine Zuteilung und nicht für Markthandel.
  • Die Gewährung stimmt die Interessen des Managements mit denen der Aktionäre ab, stellt jedoch nur einen kleinen Bruchteil der ausstehenden SEM-Aktien dar (genauer Streubesitz im Formular nicht angegeben).
Positive
  • Executive ownership increases by 75,000 shares, enhancing alignment between CIO and shareholders.
Negative
  • None.

Insights

TL;DR: Executive awarded 75k restricted shares; modest, alignment-oriented, limited dilution—neutral market impact.

The filing documents a time-vested equity grant to the CIO. Such awards are typical for retention and incentive purposes. The additional 75k shares lift total insider holdings to 376k, signaling continued commitment but not an outright open-market buy. Because the shares come from equity incentive plans, dilution impact is de minimis relative to SEM’s overall share count. No pricing, derivative activity, or concurrent sales appear, so the transaction neither conveys strong bullish nor bearish insider sentiment. I classify the market impact as neutral.

Select Medical Holdings Corp. (SEM) Modulo 4: Il Chief Information Officer Brian R. Rusignuolo ha segnalato la concessione di 75.000 azioni ordinarie il 29-lug-2025. L'assegnazione consiste in azioni vincolate che matureranno completamente il 29-lug-2028, salvo consuete eccezioni. Non è stato pagato alcun importo in contanti (prezzo segnalato $0), indicando una remunerazione basata su azioni piuttosto che un acquisto sul mercato aperto.

Dopo questa operazione, la proprietà diretta di Rusignuolo ammonta a 376.050 azioni SEM. Non sono stati coinvolti strumenti derivati né ci sono state cessioni.

  • Modulo presentato da una sola persona che segnala; nessuna indicazione di Regola 10b5-1.
  • Il codice transazione “A” indica un premio e non un'attività di mercato.
  • La concessione allinea gli interessi del dirigente con quelli degli azionisti, ma rappresenta una piccola frazione delle azioni in circolazione di SEM (la quantità esatta non è stata divulgata nel modulo).

Select Medical Holdings Corp. (SEM) Formulario 4: El Director de Información Brian R. Rusignuolo reportó la concesión de 75,000 acciones ordinarias el 29-jul-2025. La adjudicación corresponde a acciones restringidas que se consolidarán completamente el 29-jul-2028, sujeto a excepciones habituales. No se pagó efectivo (precio reportado $0), lo que indica una compensación basada en acciones en lugar de una compra en el mercado abierto.

Tras la transacción, la propiedad directa beneficiaria de Rusignuolo es de 376,050 acciones SEM. No se involucraron valores derivados ni hubo disposiciones.

  • Formulario presentado por una sola persona informante; sin indicación de la Regla 10b5-1.
  • El código de transacción “A” denota una adjudicación y no actividad de mercado.
  • La concesión alinea los intereses ejecutivos con los de los accionistas, pero representa una pequeña fracción de las acciones en circulación de SEM (el flotante exacto no se divulgó en el formulario).

Select Medical Holdings Corp. (SEM) Form 4: 최고정보책임자 브라이언 R. 루시뉴올로는 2025년 7월 29일에 75,000주의 보통주 부여를 신고했습니다. 이 수상은 제한 주식으로 2028년 7월 29일에 완전히 권리가 확정되며, 일반적인 예외 조건이 적용됩니다. 현금 지급은 없었으며(보고된 가격 $0), 이는 공개 시장에서의 매입이 아닌 주식 기반 보상임을 나타냅니다.

거래 후 루시뉴올로의 직접적 실소유 주식은 376,050 SEM 주식입니다. 파생 증권은 포함되지 않았으며 처분도 없었습니다.

  • 신고자 한 명이 제출한 서식; Rule 10b5-1 관련 표시는 없음.
  • 거래 코드 “A”는 시장 활동이 아닌 상여를 의미합니다.
  • 이번 부여는 경영진과 주주간 이해관계를 일치시키지만 SEM의 유통 주식 중 극히 일부에 해당합니다(정확한 유통 주식 수는 제출서류에 공개되지 않음).

Select Medical Holdings Corp. (SEM) Formulaire 4 : Le Directeur des Systèmes d'Information, Brian R. Rusignuolo, a déclaré l'octroi de 75 000 actions ordinaires le 29 juillet 2025. Cette attribution concerne des actions restreintes qui seront entièrement acquises le 29 juillet 2028, sous réserve des exceptions habituelles. Aucun paiement en espèces n'a été effectué (prix déclaré 0 $), ce qui indique une rémunération en actions plutôt qu'un achat sur le marché libre.

Après cette opération, la détention directe de Rusignuolo s'élève à 376 050 actions SEM. Aucun instrument dérivé n'a été impliqué et aucune cession n'a eu lieu.

  • Formulaire déposé par une seule personne déclarant ; aucune indication de la règle 10b5-1.
  • Le code de transaction « A » désigne une attribution et non une activité de marché.
  • L'attribution aligne les intérêts de la direction avec ceux des actionnaires, mais représente une faible fraction des actions en circulation de SEM (le flottant exact n'est pas divulgué dans le formulaire).

Select Medical Holdings Corp. (SEM) Formular 4: Chief Information Officer Brian R. Rusignuolo meldete die Gewährung von 75.000 Stammaktien am 29. Juli 2025. Die Zuteilung besteht aus eingeschränkten Aktien, die am 29. Juli 2028 vollständig unverfallbar sind, vorbehaltlich üblicher Ausnahmen. Es wurde kein Bargeld gezahlt (gemeldeter Preis $0), was auf eine aktienbasierte Vergütung und keinen Kauf am offenen Markt hinweist.

Nach der Transaktion hält Rusignuolo direkt 376.050 SEM-Aktien. Es waren keine Derivate beteiligt und es gab keine Veräußerungen.

  • Formular wurde von einer meldenden Person eingereicht; keine Angabe zu Regel 10b5-1.
  • Transaktionscode „A“ steht für eine Zuteilung und nicht für Markthandel.
  • Die Gewährung stimmt die Interessen des Managements mit denen der Aktionäre ab, stellt jedoch nur einen kleinen Bruchteil der ausstehenden SEM-Aktien dar (genauer Streubesitz im Formular nicht angegeben).
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KIRNBAUER EDWARD

(Last) (First) (Middle)
1900-B CARNEGIE AVENUE

(Street)
SANTA ANA CA 92705

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Identiv, Inc. [ INVE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/29/2025 A 25,000(1) A $0.00 80,561(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Restricted Stock Units granted pursuant to Issuer's 2011 Incentive Compensation Plan vesting 100% on July 11, 2026.
2. Includes an aggregate of 53,594 shares of common stock issuable pursuant to restricted stock units that have not vested.
Remarks:
Acting Chief Financial Officer and Secretary
/s/ Ed Kirnbauer 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many SEM shares did the CIO acquire on 29-Jul-2025?

The Form 4 reports an award of 75,000 restricted shares.

What is Brian R. Rusignuolo’s total ownership after the grant?

He now beneficially owns 376,050 shares of Select Medical Holdings Corp.

When will the restricted stock granted to SEM’s CIO vest?

The shares are scheduled to vest in full on 29-Jul-2028.

Was the transaction an open-market purchase?

No. Transaction code "A" indicates an equity award; the price reported was $0.

Does the filing mention any derivative securities?

No derivative securities were acquired or disposed of in this Form 4.
Identiv

NASDAQ:INVE

INVE Rankings

INVE Latest News

INVE Latest SEC Filings

INVE Stock Data

80.54M
20.64M
12.48%
54.69%
0.54%
Building Products & Equipment
Computer Peripheral Equipment, Nec
Link
United States
SANTA ANA